



## PRESS RELEASE

---

### **ILTOO Pharma will be joining the only dedicated end-to-end Treg Directed Therapy for Autoimmune Disorders Summit**



**Paris – Boston, 13<sup>th</sup> of March 2018**

ILTOO Pharma, French biotech company dedicated to the development of immunotherapies for the treatment of autoimmune and inflammatory diseases will attend and present at the inaugural Treg Summit, which is bringing for the first time the expert autoimmune community in Boston on May 22-24, to identify pioneering approaches to enhance the specificity, persistence and targeting of Treg directed therapies.

Join 80+ senior leaders from the autoimmune community, taking a closer look at pioneering research approaches to improve the functionality of Treg cells to create a safe, effective, and targeted immunotherapy. The summit will equip you with strategies to improve the targeting of Tregs for autoantigen identification as well as novel manufacturing developments to provide suitable material for future clinical proof of concept clinical trials.

Jérémie Mariau, Chief Executive Officer of ILTOO Pharma, will be presenting ILT-101 the most advanced IL2-based Tregs-directed therapy in development.

As a pioneer in the field, ILTOO Pharma will detail how this disruptive therapeutic approach consisting on selective Tregs stimulation with low dose IL2 can revolutionize the treatment of autoimmune and inflammatory diseases. This will explore the first clinical trial results and the promising therapeutic perspectives for ILT-101.

ILTOO Pharma entered into an option license agreement in May 2017 with Servier for ex-US/Japan rights with regard to ILT-101. The company has already initiated two multicentric, randomized, placebo-controlled, double-blind phase 2 clinical trials evaluating the efficacy and safety of ILT-101: DIABIL-2 study in patients with recent onset type 1 diabetes and LUPIL-2 study in patients with moderate to severe systemic lupus erythematosus, the primary completion of LUPIL-2 study being planned for the end of the year.

With 26 world leading speakers, 20+ hours of content, 2 interactive workshops and extensive networking opportunities available, this is one event not to be missed.

### **Treg Directed Therapy for Autoimmune Disorders Summit**

**May 22-May 24, 2018, Boston, USA**

#### **About ILTOO Pharma**

ILTOO Pharma is a French biotech company with its headquarters in Paris dedicated to the development of immunotherapies for the treatment of autoimmune and inflammatory diseases. ILTOO Pharma possesses a deep expertise relating to the mechanisms of regulation of the immune system in particular on the role of regulatory T lymphocytes (Tregs). The company is a global pioneer in this field. ILTOO Pharma concentrates its research efforts on two pathologies with a high unmet medical need, namely systemic lupus erythematosus and type 1 diabetes. The therapeutic potential of the technology deployed by ILTOO Pharma allows considering the treatment of many other autoimmune and inflammatory diseases.

Find out more by visiting: [www.iltoopharma.fr](http://www.iltoopharma.fr) or drop us a line at [j.mariau@iltoopharma.fr](mailto:j.mariau@iltoopharma.fr)

#### **About the Treg Directed Therapy for Autoimmune Disorders Summit**

This meeting is the first and only, dedicated, end-to-end summit focusing on targeted Treg directed therapies to cure autoimmune disorders safely and effectively. This industry focused meeting provides the platform to network, interact and learn with all of the key stakeholders in the autoimmune community. Hear the most advanced clinical case studies and innovative research methods to enhance the specificity, persistence and targeting of Treg directed therapies.

Find out more by visiting [www.treg-directed-therapies.com](http://www.treg-directed-therapies.com) or drop us a line at [info@hansonwade.com](mailto:info@hansonwade.com).